Spectral Ai, INC 8-K filings

Spectral AI, Inc. announced the appointment of Darcy Bajko as Chief Commercial Officer, effective July 31, 2026, to lead the global launch of its FDA-cleared DeepView System.

Spectral AI announced the voting results of its 2026 Annual Meeting of Stockholders, where all proposals were approved, and provided an update on its DeepView System following FDA De Novo clearance.

Spectral AI announced that the U.S. Food and Drug Administration has granted De Novo Classification for its DeepView System, authorizing commercial distribution in the United States for burn care.

Spectral AI, Inc. has formalized its CEO's employment terms, including a $500,000 base salary and significant equity grants.

Spectral AI, Inc. announced the appointment of David McGuire as its new Chief Financial Officer, effective May 4, 2026, bringing over 20 years of financial experience to the company.

Spectral AI, Inc. announced its fourth quarter and full year 2025 financial results, highlighting increased cash and progress towards commercializing its DeepView System for burn indication.

Spectral AI, Inc. announced it has received $31.7 million in non-dilutive funding from BARDA to accelerate the development of its DeepView System, an AI-driven burn wound imaging technology.

Spectral AI, a medical diagnostics AI company, announced the appointment of Vincent S. Capone as its new Chief Executive Officer, effective February 9, 2026, as it transitions towards commercialization of its DeepView System.

Colin Bristow has resigned from the Board of Directors of Spectral AI, effective immediately, with no reported disagreements.

Spectral AI, a medical diagnostics AI company, announced a $7.6 million offering of common stock and warrants to fund DeepView System expansion and 2026 commercial readiness.

Spectral AI reports Q2 2025 financial results, highlighting a significant FDA De Novo application submission and an improved cash position, despite a decline in R&D revenue.

Spectral AI announced the submission of its DeepView System, an AI-driven burn healing prediction device, for De Novo request to the U.S. Food and Drug Administration.

Spectral AI, Inc. has dismissed KPMG LLP as its independent auditor and appointed Forvis Mazars Group, citing no disagreements but acknowledging previously reported material weaknesses in internal financial controls for fiscal years 2023 and 2024.

Spectral AI, Inc. announced the formal appointment of Stanley Micek as Chief Operating Officer, transitioning from his interim role to lead operations and drive the company's FDA submission for its DeepView System.

Spectral AI, Inc. announced that its stockholders approved all proposals, including the election of six directors and the ratification of KPMG LLP as its independent registered public accounting firm, at its 2025 Annual Meeting.

Spectral AI announces improved Q1 2025 financial results with increased R&D revenue and a net income of $2.9 million, driven by progress in clinical trials and a strengthened capital structure.

Spectral AI announces its Q4 and full-year 2024 financial results, highlighting significant R&D revenue growth and successful outcomes from its US Burn Validation Study.

Spectral AI finalizes a $15 million debt agreement and a $2.7 million equity raise to advance the commercialization of its AI-driven DeepView System.

Spectral AI announces successful results from its Burn Validation Study, with its DeepView System outperforming burn physicians in identifying non-healing tissue.

Spectral AI, Inc. has entered into a securities purchase agreement for the sale of shares and pre-funded warrants, potentially raising up to $5 million.

Spectral AI enters into a securities purchase agreement with Liqueous LP, raising $2.27 million through the sale of common stock and pre-funded warrants.

Spectral AI enters into a securities purchase agreement with Liqueous LP for up to $5 million through the issuance of common stock and pre-funded warrants.

Spectral AI has announced that it has regained compliance with Nasdaq listing requirements, avoiding a further hearing.

Spectral AI, Inc. has received a delisting notice from Nasdaq after failing to maintain a minimum market value of $35 million, and has requested a hearing to present a compliance plan.

Spectral AI's founder, Dr. J. Michael DiMaio, returns as Chairman of the Board, while CEO Peter M. Carlson resigns, effective October 14, 2024.

Spectral AI is advancing its DeepView AI-driven wound assessment technology, targeting large markets with a focus on burn and diabetic foot ulcer care.

Spectral AI is actively pursuing a Nasdaq investigation into potential market manipulation of its stock, primarily through naked short selling.

Spectral AI has requested an inquiry into potential market manipulation of its stock, specifically citing concerns about naked short selling.

Spectral AI, Inc. received a notice from Nasdaq for not maintaining the minimum market value of listed securities, placing it at risk of potential delisting.

Spectral AI held its 2024 Annual Meeting, expanding its board and securing shareholder approval for key proposals including a new long-term incentive plan and a standby equity purchase agreement.